Featured

FDA Approves Atzumi™ for Acute Migraine Treatment

Satsuma Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Atzumi™ (dihydroergotamine (DHE)) nasal powder for the...

Home/KnolSights/Regulatory Approvals/FDA Approves Atzumi™ for Acute Migraine Treatment